Founded by Brian Gladsden, Mosaic TX is revolutionizing the fight against cancer with its cutting-edge approach to targeted oncology therapeutics. The biotech startup has raised an impressive $28 million in Series A funding, with Cambridge Innovation Capital and Syncona Limited among its investors. Mosaic's unique platform combines computational and experimental medicine to develop novel targeted therapies for patients in biomarker-defined settings, paving the way for safer and more effective cancer treatments. With a large-scale, agnostic, and prospective approach, Mosaic is reinventing the traditional methods of drug discovery and target identification. 

Its proprietary, wet and dry lab platform features over 1300 deeply characterized 2D and 3D tumor models, genome-scale CRISPR screening capabilities, and an industry-validated PRIME computational pipeline. Mosaic's research is rooted in pioneering work in translational functional genomics at the Wellcome Sanger Institute, in collaboration with the Netherlands Cancer Institute, which forms the scientific foundation of its R&D engine. By enabling molecularly-guided stratification, Mosaic is moving towards more effective and less toxic medicines for patients, resolving cancer's complexity in a way that was once thought impossible.